Tela Competitors

TELA Stock

USD 0.72 0.08 10.00%

Tela Bio competes with Spectral, Icecure Medical, Cue Biopharma, NRX Pharmaceuticals, and Cytosorbents Crp; as well as few others. The company conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. Analyzing Tela Bio competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Tela Bio to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Tela Bio Correlation with its peers.

For information on how to trade Tela Stock refer to our How to Trade Tela Stock guide.

Tela Bio vs Equillium Correlation

Excellent diversification

The correlation between Tela Bio and EQ is -0.63 (i.e., Excellent diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Tela Bio and EQ in the same portfolio, assuming nothing else is changed.

Moving together with Tela Stock

0.72	IL3	Integra LifeSciences Earnings Call This Week	Pair Corr
0.86	EW	Edwards Lifesciences Corp	Pair Corr

Moving against Tela Stock

0.91	HYB	HOYA	Pair Corr
0.79	EKSO	Ekso Bionics Holdings	Pair Corr
0.76	VREX	Varex Imaging Corp	Pair Corr
0.74	EDAP	EDAP TMS SA	Pair Corr
0.55	DXCM	DexCom Inc	Pair Corr

As of February 22, 2026, Return On Tangible Assets is expected to decline to -0.42. In addition to that, Return On Capital Employed is expected to decline to -0.45. At present, Tela Bio's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 11.2 M, whereas Total Assets are forecasted to decline to about 67.8 M.

Specify up to 10 symbols:

Hype

Prediction

Low	Estimated	High
0.04	0.73	3.86

Details

Intrinsic

Valuation

Low	Real	High
0.07	1.40	4.53

Details

Naive

Forecast

Low	Next	High
0.01	0.72	3.85

Details

5 Analysts

Consensus

Low	Target	High
3.14	3.45	3.83

Details

Tela Bio Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Tela Bio and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Tela and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Tela Bio does not affect the price movement of the other competitor.

	MDAI	ICCM	CUE	NRXP	CTSO	SRTS	COEP	OTLK	SPRB	EQ
MDAI		0.17	0.27	-0.07	0.21	0.54	0.11	-0.25	0.22	-0.21	MDAI
ICCM	0.17		0.64	0.66	0.68	-0.16	0.84	0.56	0.62	-0.61	ICCM
CUE	0.27	0.64		0.25	0.73	-0.18	0.76	0.51	0.63	-0.6	CUE
NRXP	-0.07	0.66	0.25		0.37	-0.27	0.68	0.52	0.55	-0.26	NRXP
CTSO	0.21	0.68	0.73	0.37		-0.05	0.7	0.43	0.6	-0.53	CTSO
SRTS	0.54	-0.16	-0.18	-0.27	-0.05		-0.3	-0.67	0.04	0.13	SRTS
COEP	0.11	0.84	0.76	0.68	0.7	-0.3		0.68	0.8	-0.51	COEP
OTLK	-0.25	0.56	0.51	0.52	0.43	-0.67	0.68		0.47	-0.44	OTLK
SPRB	0.22	0.62	0.63	0.55	0.6	0.04	0.8	0.47		-0.3	SPRB
EQ	-0.21	-0.61	-0.6	-0.26	-0.53	0.13	-0.51	-0.44	-0.3		EQ
	MDAI	ICCM	CUE	NRXP	CTSO	SRTS	COEP	OTLK	SPRB	EQ

Please upgrade your account to get full access to Macroaxis premium features

High positive correlations

COEP	+ 0.84	ICCM
SPRB	+ 0.8	COEP
COEP	+ 0.76	CUE
CTSO	+ 0.73	CUE
COEP	+ 0.7	CTSO
CTSO	+ 0.68	ICCM

High negative correlations

OTLK	- 0.67	SRTS
EQ	- 0.61	ICCM
EQ	- 0.6	CUE
EQ	- 0.53	CTSO
EQ	- 0.51	COEP
EQ	- 0.44	OTLK

Risk-Adjusted Indicators

There is a big difference between Tela Stock performing well and Tela Bio Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Tela Bio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
MDAI	2.92	(0.11)	0.00	(0.03)	0.00	0.00	5.84	(6.87)	17.06
ICCM	2.22	(0.30)	0.00	0.81	0.00	0.00	3.28	(5.63)	14.72
CUE	5.64	(0.91)	0.00	(2.72)	0.00	0.00	9.68	(12.50)	50.98
NRXP	3.87	(0.20)	0.00	0.78	0.00	0.00	7.34	(7.26)	19.22
CTSO	3.45	(0.05)	0.00	0.04	3.95	(5.04)	7.94	(7.41)	29.40
SRTS	2.79	(0.15)	0.00	(0.04)	0.00	0.00	7.45	(6.04)	31.96
COEP	3.18	(0.62)	0.00	(3.57)	0.00	0.00	7.44	(6.83)	28.94
OTLK	5.85	(1.81)	0.00	(1.60)	0.00	0.00	11.32	(14.29)	72.05
SPRB	4.90	(1.13)	0.00	(0.83)	0.00	0.00	8.53	(11.55)	36.59
EQ	4.99	0.95	0.15	0.91	5.18	(6.34)	18.89	(9.09)	43.07

Cross Equities Net Income Analysis

Compare Tela Bio and related stocks such as Spectral AI, Icecure Medical, and Cue Biopharma Net Income Over Time

Select Fundamental

	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
CTSO	(80 K)	(5.5 M)	(3.7 M)	(4.7 M)	(9.3 M)	(8.1 M)	(11.9 M)	(8.5 M)	(17.2 M)	(19.3 M)	(7.8 M)	(24.6 M)	(32.8 M)	(29.2 M)	(20.7 M)	(18.6 M)	(17.7 M)
SRTS	107.6 K	107.6 K	107.6 K	107.6 K	(3.7 M)	(237.3 K)	(346.4 K)	(3.7 M)	(2 M)	(1.7 M)	(6.8 M)	4.1 M	24.2 M	485 K	6.6 M	(7.7 M)	(7.3 M)
EQ	(2.3 M)	(2.3 M)	(2.3 M)	(2.3 M)	(2.3 M)	(2.3 M)	(2.3 M)	(2.3 M)	(13.2 M)	(25.6 M)	(29.8 M)	(39 M)	(62.4 M)	(13.3 M)	(8.1 M)	(7.3 M)	(7.6 M)

Tela Bio and related stocks such as Spectral AI, Icecure Medical, and Cue Biopharma Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Tela Bio financial statement analysis. It represents the amount of money remaining after all of Tela Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Tela Bio Competitive Analysis

The better you understand Tela Bio competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Tela Bio's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Tela Bio's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	TELA	MDAI	ICCM	CUE	NRXP	CTSO	SRTS	COEP	OTLK	SPRB
	10.00 0.72 Tela	3.36 1.44 Spectral	1.72 0.57 Icecure	3.45 0.28 Cue	3.37 1.84 NRX	1.54 0.64 Cytosorbents	1.02 3.95 Sensus	0.69 11.49 Coeptis	4.65 0.41 OUTLOOK	5.51 49.72 Spruce
Market Volatility (90 Days Market Risk)	Very risky	Very risky	Dangerous	Abnormally volatile	Slightly risky	Dangerous	Relatively risky	Relatively risky	Abnormally volatile	Very steady
Market Performance (90 Days Performance)	Weakest	Weakest	Weakest	Weakest	Weakest	Weakest	Weak	Weakest	Weakest	Weakest
Odds of Financial Distress (Probability Of Bankruptcy)	Risky	Risky	Small	Risky	High	Risky	Low	Low	Risky	High
Current Valuation (Equity Enterprise Value)	Under Valued	Under Valued	Under Valued	Under Valued	Under Valued	Under Valued	Under Valued	Over Valued	Under Valued	Under Valued
Buy or Sell Advice (Average Analysts Consensus)	Strong Buy	Not Available	Not Available	Not Available	Not Available	Buy	Strong Buy	Not Available	Not Available	Not Available
Trade Advice (90 Days Macroaxis Advice)	Strong Sell	Strong Sell	Strong Sell	Strong Sell	Strong Sell	Strong Sell	Sell	Sell	Strong Sell	Cautious Hold
Current Ratio	3.83	N/A	4.99	8.29	4.58	3.95	5.01	0.56	2.04	9.55
Net Asset	87.33 M	12.1 M	12.58 M	32.19 M	3.65 M	47.37 M	53.04 M	8.91 M	18.58 T	45.21 M
Profit Margin	-0.51	-0.71	N/A	N/A	N/A	-0.28	-0.28	N/A	N/A	N/A
EBITDA	(31.68 M)	(11.49 M)	(15.36 M)	(37.53 M)	(24.04 M)	(15.22 M)	(9.92 M)	(9.44 M)	(63.58 M)	(52.68 M)
Operating Margin	-0.37	-0.88	-4.51	-3.51	-17.02	-0.28	0.41	-22.53	11.16	-71.0
Current Valuation	47.44 M	43.36 M	29.59 M	13.49 M	56.51 M	59.88 M	41.94 M	64.73 M	58.13 M	61.63 M
Price To Book	22.03	29.88	4.27	1.96	2.9	4.47	1.24	6.73	10.19	13.17
Retained Earnings	(358.73 M)	(48.1 M)	(105.38 M)	(341.86 M)	(278.27 M)	(304.01 M)	5.71 M	(98.23 M)	(605.71 T)	(250.27 M)
Current Asset	N/A	N/A	N/A	42.21 M	N/A	9.05 M	N/A	N/A	4.12 M	N/A
Beta	0.87	0.95	2.21	1.5	1.96	1.41	1.19	-0.5	-0.067	3.61
Number Of Employees	209	78	64	41	15	149	54	5	17	9
Shares Outstanding	44.53 M	30.69 M	68.96 M	91.24 M	29.61 M	62.8 M	16.47 M	4.82 M	73.51 M	1.07 M
Cash Flow From Operations	(41.59 M)	(9.2 M)	(12.56 M)	(36.33 M)	(10.64 M)	(14.43 M)	(831 K)	(6.65 M)	(51.83 T)	(55.96 M)
Total Debt	43.06 M	4.69 M	459 K	8.88 M	6.58 M	26.89 M	680 K	1.4 M	247.7 B	2.77 M
Return On Equity	-6.76	-23.08	-1.58	-1.95	-6.83	-0.93	-0.15	-3.72	-0.0365	-1.68
Return On Asset	-0.39	-0.35	-0.63	-0.62	-0.98	-0.19	-0.11	-0.98	-2.09	-0.77
Number Of Shares Shorted	508.38 K	1.48 M	548.03 K	2.17 M	2.78 M	2.04 M	579.39 K	453.79 K	4.55 M	71.75 K
Book Value Per Share	0.039	-0.3	0.14	0.17	-0.93	0.14	1.57	1.46	-0.6	9.56
Current Liabilities	N/A	N/A	N/A	3.38 M	N/A	5 M	N/A	N/A	28.27 M	N/A
Total Asset	87.33 M	12.1 M	12.58 M	32.19 M	3.65 M	47.37 M	53.04 M	8.91 M	18.58 T	45.21 M
Debt To Equity	3.33	N/A	0.039	0.33	0.016	0.28	0.024	1.89	0.52	0.071
Short Ratio	7.95	4.09	1.83	1.14	1.66	23.21	4.86	1.67	0.39	2.48
Target Price	3.45	5.36	3.13	4.0	36.75	5.25	6.67	3.0	5.38	205.75
Shares Owned By Institutions	72.01	15.2	0.67	27.69	28.1	27.01	29.53	3.9	8.22	77.12
Market Capitalization	31.95 M	44.19 M	39.39 M	25.98 M	54.47 M	40.21 M	65.04 M	68.21 M	30.37 M	53.22 M
Price To Earning	N/A	N/A	N/A	-2.17	N/A	-16.3	4.3	N/A	-1.24	N/A
Price To Sales	0.41	1.91	13.24	3.66	225.1	1.09	2.37	132.15	147.63	76.35
Net Income	(37.84 M)	(15.31 M)	(15.32 M)	(40.67 M)	(25.13 M)	(20.72 M)	(7.72 M)	(10.88 M)	(62.42 T)	(53.04 M)
Earnings Per Share	-0.83	-0.75	-0.25	-0.41	-2.31	-0.18	-0.47	-6.87	-2.89	-84.32
Shares Owned By Insiders	8.44	25.64	40.4	0.74	9.27	15.77	18.2	13.39	18.45	9.11
Revenue	69.3 M	29.58 M	3.29 M	9.29 M	N/A	35.59 M	27.48 M	N/A	1.41 M	4.91 M
Working Capital	62.47 M	(7.52 M)	5.24 M	11.45 M	(18.56 M)	11.78 M	50.85 M	(3.46 M)	(28.43 M)	28.96 M
Cash And Equivalents	27.73 M	N/A	17.73 M	66.13 M	24.55 M	30.16 M	33.7 M	2.38 M	26.02 M	93.3 M
Cash Per Share	1.9	N/A	0.48	1.87	0.36	0.69	2.04	0.06	0.12	3.96
Gross Profit	52.19 M	10.43 M	1.04 M	(28.32 M)	145 K	26.18 M	11.87 M	173.24 K	(22.34 M)	(36.18 M)
Day Typical Price	0.72	1.45	0.58	0.29	1.82	0.65	3.92	11.52	0.42	50.69
Accumulation Distribution	0.14	0.0338	0.05	0.0667	0.0432	0.0448	0.0327	0.0622	0.0889	0.11
Market Facilitation Index	0.11	0.05	0.03	0.02	0.08	0.03	0.13	0.74	0.04	6.19
Daily Balance Of Power	(0.73)	(1.00)	(0.33)	(0.50)	0.75	(0.33)	0.3077	(0.11)	(0.50)	(0.47)
Period Momentum Indicator	(0.08)	(0.05)	(0.01)	(0.01)	0.06	(0.01)	0.04	(0.08)	(0.02)	(2.90)
Rate Of Daily Change	0.9	0.97	0.98	0.97	1.03	0.98	1.01	0.99	0.95	0.94
Day Median Price	0.73	1.46	0.59	0.29	1.81	0.66	3.91	11.53	0.43	51.18
Price Action Indicator	(0.04)	(0.04)	(0.02)	(0.01)	0.06	(0.02)	0.065	(0.08)	(0.03)	(2.91)
Relative Strength Index	38.1	51.78	39.36	46.34	45.1	50.62	60.84	52.07	20.62	45.12
Coefficient Of Variation	(932.91)	(18,118)	(916.96)	(956.69)	(2,293)	6037.19	(9,734)	(769.08)	(576.90)	(629.11)
Mean Deviation	2.8	2.92	2.22	5.64	3.87	3.45	2.79	3.18	5.85	4.9
Jensen Alpha	(0.43)	(0.11)	(0.30)	(0.91)	(0.20)	(0.05)	(0.15)	(0.62)	(1.81)	(1.13)
Total Risk Alpha	(0.79)	(0.37)	(0.60)	(1.67)	(0.66)	(0.42)	(0.45)	(1.03)	(2.65)	(1.65)
Sortino Ratio	N/A	N/A	N/A	N/A	N/A	0.0015	N/A	N/A	N/A	N/A
Downside Variance	N/A	N/A	N/A	N/A	N/A	26.31	N/A	N/A	N/A	N/A
Standard Deviation	3.93	3.72	2.91	8.43	4.8	5.34	4.29	4.57	9.93	6.51
Kurtosis	2.88	0.1292	0.7139	5.33	(0.05)	4.02	4.78	4.39	16.88	1.04
Potential Upside	5.36	5.84	3.28	9.68	7.34	7.94	7.45	7.44	11.32	8.53
Treynor Ratio	(7.63)	(0.03)	0.8051	(2.72)	0.7791	0.043	(0.04)	(3.57)	(1.60)	(0.83)
Maximum Drawdown	22.82	17.06	14.72	50.98	19.22	29.4	31.96	28.94	72.05	36.59
Variance	15.43	13.86	8.49	70.99	23.04	28.51	18.4	20.9	98.6	42.32
Market Risk Adjusted Performance	(7.62)	(0.02)	0.8151	(2.71)	0.7891	0.053	(0.03)	(3.56)	(1.59)	(0.82)
Risk Adjusted Performance	(0.07)	0.0037	(0.08)	(0.07)	(0.02)	0.0212	4.0E-4	(0.09)	(0.12)	(0.11)
Skewness	0.5453	0.1536	0.2373	1.36	0.3368	1.3	(0.10)	(0.87)	(3.06)	(0.29)
Semi Deviation	N/A	N/A	N/A	N/A	N/A	3.95	N/A	N/A	N/A	N/A
Information Ratio	(0.13)	(0.03)	(0.14)	(0.11)	(0.06)	0.0015	(0.03)	(0.15)	(0.18)	(0.17)
Value At Risk	(8.42)	(6.88)	(5.63)	(12.50)	(7.26)	(7.41)	(6.04)	(6.83)	(14.29)	(11.55)
Expected Short fall	N/A	N/A	N/A	N/A	N/A	(5.04)	N/A	N/A	N/A	N/A
Downside Deviation	N/A	N/A	N/A	N/A	N/A	5.13	N/A	N/A	N/A	N/A
Semi Variance	N/A	N/A	N/A	N/A	N/A	15.57	N/A	N/A	N/A	N/A

Tela Bio Competition Performance Charts

Five steps to successful analysis of Tela Bio Competition

Tela Bio's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Tela Bio in relation to its competition. Tela Bio's competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of Tela Bio in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Tela Bio's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Tela Bio, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Tela Bio position

In addition to having Tela Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run SPAC Thematic Idea Now

SPAC

Entities that are involved in raising capital, merging with and acquiring companies, and investing in private equity through leveraged buyouts. The SPAC theme has 25 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize SPAC Theme or any other thematic opportunities.

View All Next

Launch

When determining whether Tela Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tela Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tela Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tela Bio Stock:

How To Invest In Tela

Details

Is Tela Stock a good investment?

Details

What is Tela Bio's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Tela Bio Correlation with its peers.

For information on how to trade Tela Stock refer to our How to Trade Tela Stock guide.

You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tela Bio. If investors know Tela will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Tela Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.

Earnings Share

(0.83)

Revenue Per Share

1.749

Quarterly Revenue Growth

0.091

Return On Assets

(0.39)

Return On Equity

(6.76)

The market value of Tela Bio is measured differently than its book value, which is the value of Tela that is recorded on the company's balance sheet. Investors also form their own opinion of Tela Bio's value that differs from its market value or its book value, called intrinsic value, which is Tela Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tela Bio's market value can be influenced by many factors that don't directly affect Tela Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Tela Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tela Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Tela Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Cash Conversion Cycle	Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding	Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity

Tela Competitors

Tela Bio vs Equillium Correlation

Excellent diversification

Moving together with Tela Stock

Moving against Tela Stock

Specify up to 10 symbols:

Tela Bio Competition Correlation Matrix

High positive correlations

High negative correlations

Risk-Adjusted Indicators

Cross Equities Net Income Analysis

Tela Bio and related stocks such as Spectral AI, Icecure Medical, and Cue Biopharma Net Income description

Tela Bio Competitive Analysis

Tela Bio Competition Performance Charts

Five steps to successful analysis of Tela Bio Competition

Complement your Tela Bio position

Did You Try This Idea?

Run SPAC Thematic Idea Now

SPAC

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY